JP6345123B2 - 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 - Google Patents

抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 Download PDF

Info

Publication number
JP6345123B2
JP6345123B2 JP2014557754A JP2014557754A JP6345123B2 JP 6345123 B2 JP6345123 B2 JP 6345123B2 JP 2014557754 A JP2014557754 A JP 2014557754A JP 2014557754 A JP2014557754 A JP 2014557754A JP 6345123 B2 JP6345123 B2 JP 6345123B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
vla
aqueous pharmaceutical
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014557754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508774A5 (enExample
JP2015508774A (ja
Inventor
アダム ジェレミー フォウラー，
アダム ジェレミー フォウラー，
クレッグ マイケル バウ，
クレッグ マイケル バウ，
ウェイン カーティス ヤント，
ウェイン カーティス ヤント，
ネイサン ジェレミー コブ，
ネイサン ジェレミー コブ，
ティモシー マーティン ケリー，
ティモシー マーティン ケリー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santarus Inc
Original Assignee
Santarus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santarus Inc filed Critical Santarus Inc
Publication of JP2015508774A publication Critical patent/JP2015508774A/ja
Publication of JP2015508774A5 publication Critical patent/JP2015508774A5/ja
Application granted granted Critical
Publication of JP6345123B2 publication Critical patent/JP6345123B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2014557754A 2012-02-16 2013-02-14 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 Expired - Fee Related JP6345123B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599827P 2012-02-16 2012-02-16
US61/599,827 2012-02-16
PCT/US2013/026034 WO2013123114A2 (en) 2012-02-16 2013-02-14 Antibody formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018097486A Division JP6759276B2 (ja) 2012-02-16 2018-05-22 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物

Publications (3)

Publication Number Publication Date
JP2015508774A JP2015508774A (ja) 2015-03-23
JP2015508774A5 JP2015508774A5 (enExample) 2016-03-24
JP6345123B2 true JP6345123B2 (ja) 2018-06-20

Family

ID=47997774

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014557754A Expired - Fee Related JP6345123B2 (ja) 2012-02-16 2013-02-14 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
JP2018097486A Expired - Fee Related JP6759276B2 (ja) 2012-02-16 2018-05-22 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018097486A Expired - Fee Related JP6759276B2 (ja) 2012-02-16 2018-05-22 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物

Country Status (11)

Country Link
US (5) US10160808B2 (enExample)
EP (1) EP2814468B1 (enExample)
JP (2) JP6345123B2 (enExample)
CN (1) CN104271122A (enExample)
AU (2) AU2013221635B2 (enExample)
CA (1) CA2864539C (enExample)
ES (1) ES2732243T3 (enExample)
IL (1) IL233976B (enExample)
MX (1) MX370199B (enExample)
NZ (1) NZ629204A (enExample)
WO (1) WO2013123114A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138614A (ja) * 2012-02-16 2018-09-06 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181054A1 (en) 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
EP1423431B1 (en) 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
WO2015136472A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg4-5
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
US20160089401A1 (en) * 2014-09-29 2016-03-31 Cook General Biotechnology Llc Uses of trehalose in cell suspensions
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US20160367180A1 (en) * 2015-06-17 2016-12-22 Obsevera, Inc. Apparatus and method of conducting medical evaluation of add/adhd
WO2017046776A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
US11286307B2 (en) * 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
EP3430052A2 (en) * 2016-03-14 2019-01-23 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
EA201892735A1 (ru) * 2016-06-16 2019-05-31 Янссен Вэксинс Энд Превеншн Б.В. Состав вакцины против hiv
UA122610C2 (uk) * 2016-06-30 2020-12-10 Селлтріон Інк. Стабільний рідкий фармацевтичний склад
WO2019018688A1 (en) * 2017-07-20 2019-01-24 The University Of Virginia Patent Foundation METHODS OF TREATING OR PREVENTING A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM
US20210100837A1 (en) * 2017-12-14 2021-04-08 The University Of Chicago Treatment of fibrosis with genetically-engineered macrophages
BR112020015052A2 (pt) * 2018-02-09 2020-12-08 Genmab A/S Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
MA54752A (fr) * 2019-01-14 2021-11-24 Univ Virginia Patent Foundation Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux
WO2020216847A1 (en) * 2019-04-23 2020-10-29 Sanofi Stable, low-viscosity antibody formulations and uses thereof
AU2020328195A1 (en) * 2019-08-15 2022-03-03 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies directed against CD3 and CD20 and their uses
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
KR20230008775A (ko) 2020-05-08 2023-01-16 젠맵 에이/에스 Cd3 및 cd20에 대한 이중특이적 항체
CN116437956A (zh) 2020-09-10 2023-07-14 健玛保 用于治疗慢性淋巴细胞白血病的针对cd3和cd20的双特异性抗体
WO2022053654A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
WO2022053657A1 (en) 2020-09-10 2022-03-17 Genmab A/S Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
IL301086A (en) 2020-09-10 2023-05-01 Genmab As Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
JP2023542290A (ja) 2020-09-10 2023-10-06 ジェンマブ エー／エス 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2026062206A2 (en) 2024-09-20 2026-03-26 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) A method of differentiating human embryonic stem cells into beta cells via camp signalling pathway promotion

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US6111598A (en) 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE69535133T2 (de) 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
ATE195428T1 (de) 1994-04-26 2000-09-15 Kanebo Ltd Arznei für rheumatoide arthritis
JPH08131185A (ja) 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6127524A (en) 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
ES2285841T3 (es) 1998-05-22 2007-11-16 Boys Town National Research Hospital Uso de inhibidores del receptor de integrina alfa1beta1 e inhibidores de tgf-beta1 en el tratamiento de la enfermedad renal.
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
AU751157B2 (en) 1998-10-06 2002-08-08 Biogen Idec Ma Inc. Crystals of the alpha 1 beta 1 integrin I-domain and their use
ES2243259T3 (es) 1999-04-22 2005-12-01 Biogen Idec Ma Inc. Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina.
EP1181054A1 (en) 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
EP1408839A1 (de) 1999-06-17 2004-04-21 Kai Dr. Desinger Chirurgische sonde zur minimal invasiven gewebeentnahme
AU4259901A (en) 2000-03-28 2001-10-08 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
EP1423431B1 (en) 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
US20030138417A1 (en) * 2001-11-08 2003-07-24 Kaisheva Elizabet A. Stable liquid pharmaceutical formulation of IgG antibodies
AU2003215298A1 (en) 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
KR101115797B1 (ko) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법
US20040208870A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
JP2006516636A (ja) * 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
WO2005019177A1 (en) 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CA2652815C (en) * 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
US7626243B2 (en) 2006-08-04 2009-12-01 Advanced Analogic Technologies, Inc. ESD protection for bipolar-CMOS-DMOS integrated circuit devices
CA2690382A1 (en) * 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
WO2010027766A1 (en) * 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
SG184355A1 (en) * 2010-03-01 2012-11-29 Progenics Pharm Inc Concentrated protein formulations and uses thereof
RU2012153786A (ru) * 2010-05-28 2014-07-10 Ново Нордиск А/С Стабильные многодозовые композиции, содержащие антитело и консервант
CA2824089A1 (en) 2011-02-03 2012-08-09 Santarus, Inc. Selection and treatment of subjects
US9018035B2 (en) 2012-01-11 2015-04-28 Panasonic Intellectual Property Management Co., Ltd. Pressed-contact type semiconductor device and method for manufacturing the same
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018138614A (ja) * 2012-02-16 2018-09-06 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物

Also Published As

Publication number Publication date
CA2864539A1 (en) 2013-08-22
AU2013221635B2 (en) 2017-12-07
WO2013123114A2 (en) 2013-08-22
EP2814468A2 (en) 2014-12-24
MX370199B (es) 2019-12-05
US20160017043A1 (en) 2016-01-21
IL233976A0 (en) 2014-09-30
US10316095B2 (en) 2019-06-11
EP2814468B1 (en) 2019-06-19
AU2013221635A1 (en) 2014-09-18
US20190338036A1 (en) 2019-11-07
JP2018138614A (ja) 2018-09-06
US10160808B2 (en) 2018-12-25
US20130216556A1 (en) 2013-08-22
NZ629204A (en) 2016-09-30
WO2013123114A3 (en) 2013-12-05
AU2013221635A2 (en) 2014-12-11
CN104271122A (zh) 2015-01-07
IL233976B (en) 2018-08-30
ES2732243T3 (es) 2019-11-21
JP6759276B2 (ja) 2020-09-23
AU2017265049B2 (en) 2019-10-24
CA2864539C (en) 2022-06-07
MX2014009755A (es) 2015-02-24
US20140010827A1 (en) 2014-01-09
JP2015508774A (ja) 2015-03-23
HK1199620A1 (en) 2015-07-10
US20190194331A1 (en) 2019-06-27
AU2017265049A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
JP6759276B2 (ja) 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
JP7277649B2 (ja) 高濃度抗ｃ５抗体製剤
TWI614028B (zh) 抗體調配物
JP2021152021A (ja) 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用
CN107252483A (zh) 受试者的选择和治疗
HK1199620B (en) Anti-vla1 (cd49a) antibody pharmaceutical compositions
KR20230026407A (ko) 액티빈 a 항체 제형 및 이의 사용 방법
HK40006379A (en) Natalizumab antibody formulations
HK1143060B (en) Natalizumab antibody formulations
HK1143060A (en) Natalizumab antibody formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170106

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20170106

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180424

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180522

R150 Certificate of patent or registration of utility model

Ref document number: 6345123

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees